大肠癌亲和酶标法检测雌孕激素受体及临床生物学意义

目的探讨雌孕激素受体与结直肠癌病理、临床及生物学行为的关系。方法应用免疫组织化学的亲和酶标法检测５３例结直肠癌的雌激素受体和孕激素受体。结果雌孕激素受体总阳性率为６０％（３２／５３）；女性和男性阳性率分别为７５％（２１／２８）和４４％（１１／２５），差异有显著意义（Ｐ＜０．０５）。管状乳头状腺癌受体阳性率为７０％，高于印戒细胞和粘液腺癌３８％（Ｐ＜０．０５）；ＤｕｋｅｓＢ期受体阳性率为７５％，高于Ｄ期３３％（Ｐ＜０．０５）；淋巴无转移者受体阳性率为８５％，高于有转移者４５％（Ｐ＜０．０５）。肿瘤体积＜５ｃｍ３者受体阳性率为７１％，高于≥５ｃｍ３者３９％（Ｐ＜０．０５）。直肠癌受体阳性率为７１％，高于结肠癌３３％（Ｐ＜０．０５）。高分化癌受体阳性率为７８％，高于低分化癌３５％（Ｐ＜０．０５）。结论女性大肠癌发病与受体关系密切；受体作用失常参与大肠癌发病始于较早期阶段；直肠癌发病与受体密度增高关系更为密切。     

宫颈鳞状细胞癌雌、孕激素受体水平与预后的关系──附126例临床病理分析

本文采用酶联亲和组化标记法测定了１２６例宫颈鳞状细胞癌雌激素受体（ＥＲ），并对其中９４例测定了孕激素受体（ＰＲ）。结果表明：ＥＲ阳性率４４．４％（５６／１２６），ＰＲ阳性率３０．８％（２９／９４），ＥＲ、ＰＲ皆阳性率２４．４％（２３／９４）。ＥＲ、ＰＲ水平与病理组织学分级（Ｐ＜０．０１，Ｐ＜０．０５）及生存率（Ｐ＜０．０５）均有明显的关系，这说明ＥＲ、ＰＲ水平越高，癌组织的分化程度越高，其生存期越长。因此，测定宫颈癌ＥＲ、ＰＲ对判断预后及指导临床选择性内分泌治疗均有重大作用。     

宫颈鳞状细胞癌雌、孕激素受体水平与预后的关系──附126例临床病理分析

本文采用酶联亲和组化标记法测定了１２６例宫颈鳞状细胞癌雌激素受体（ＥＲ），并对其中９４例测定了孕激素受体（ＰＲ）。结果表明：ＥＲ阳性率４４．４％（５６／１２６），ＰＲ阳性率３０．８％（２９／９４），ＥＲ、ＰＲ皆阳性率２４．４％（２３／９４）。ＥＲ、ＰＲ水平与病理组织学分级（Ｐ＜０．０１，Ｐ＜０．０５）及生存率（Ｐ＜０．０５）均有明显的关系，这说明ＥＲ、ＰＲ水平越高，癌组织的分化程度越高，其生存期越长。因此，测定宫颈癌ＥＲ、ＰＲ对判断预后及指导临床选择性内分泌治疗均有重大作用。     

甲状腺癌,腺瘤及正常甲状腺组织女性激素受体检测的临床…

采用酶联亲和组化法于石蜡切片对６７例甲状腺癌，２０例腺瘤及３３例瘤旁正常甲状腺组织进行了雌激素受体（ＥＲ）和孕激素受体（ＰｇＲ）检测。结果显示：在腺癌中ＥＲ、ＰｇＲ阳性表达明显高于腺瘤及正常组织（Ｐ〈０．０１），癌组织中乳头状癌阳性率最高，滤泡状癌次之，未分化及其它癌最低，４０岁以前癌组织中ＰｇＲ阳性率高于４０岁以后（Ｐ〈０．０５），女性癌组织中ＰｇＲ阳性率高于男性（Ｐ〈０．０５）。提示，ＥＲ，Ｐ     

胰腺导管腺癌甾体激素受体的检测及其意义

目的 探讨胰腺癌甾体激素受体状态及其生物学特征。方法 采用Ｓ－Ｐ免疫组化方法对５０例胰腺导管腺癌雌激素受体（ＥＲ），孕激素受体（ＰＲ）进行检测，结果 胰腺导管腺癌ＥＲ阳性率５０．０％（２５／５０）ＰＲ阳性率４６．０％（２３／５０），ＥＲ，ＰＲ状态与癌组织分化程度密切相关（Ｐ〈０．０１）癌组织分化越好，ＥＲ，ＰＲ水平越高。无转移的胰腺癌ＥＲ水平高于有转移灶者（Ｐ〈０．０５），ＥＲ，ＰＲ水平与性别，年     

胰腺导管腺癌甾体激素受体的检测及其意义

目的探讨胰腺癌甾体激素受体状态及其生物学特征。方法采用Ｓ－Ｐ免疫组化方法对５０例胰腺导管腺癌雌激素受体（ＥＲ）、孕激素受体（ＰＲ）进行检测。结果胰腺导管腺癌ＥＲ阳性率５０．０％（２５／５０）ＰＲ阳性率４６．０％（２３／５０）。ＥＲ、ＰＲ状态与癌组织的分化程度密切相关（Ｐ＜０．０１），癌组织分化越好，ＥＲ、ＰＲ水平越高。无转移的胰腺癌ＥＲ水平高于有转移灶者（Ｐ＜０．０５）。ＥＲ、ＰＲ水平与性别、年龄、ＴＭＭ分期均无明显关系（Ｐ＞０．０５）。结论胰腺癌组织内存在ＥＲ、ＰＲ，其水平反映了胰腺癌的生物学特性     

DCC法检测食管鳞癌组织中雌,孕激素胞浆,胞核受体

对３０例原发食管鳞癌组织及１６例正常食管组织中雌、孕激素受体在胞浆和胞核（ＥＲｃ、ＥＲｎ、ＰｇＲｃ、ＰｇＲｎ）中分布进行分析，结果显示：正常食管组织中ＥＲｃ、ＥＲｎ、ＰｇＲｃ和ＰｇＲｎ均未检出；癌组织中上述受体含量分别为０～８４．６ｆｍｏｌ／ｍｇ蛋白、０～８７．７ｆｍｏｌ／ｍｇＤＮＡ、０～６８．０ｆｍｏｌ／ｍｇ蛋白和０～６９．４ｆｍｏｌ／ｍｇＤＮＡ，阳性率分别为３６．７％、３３．３％、３０％和３０％，受体含量及阳性率均明显高于正常食管组织（Ｐ＜０．０５）。上述受体阳性率随癌组织学分级增加而明显下降，且女性高于男性（Ｐ＜０．０５）。     

食管鳞状上皮癌雌激素受体和孕激素受体的研究

应用酶联亲和组化法对５４例食管鳞状上皮癌及１２例正常食管粘膜进行雌激素受体和孕激素受体检测。结果表明，食管鳞状上皮癌的雌激素受体阳性率为４２．６％，孕激素受体阳性率为３７．０％。正常食管粘膜均为阴性。提示食管鳞状上皮癌中确有雌激素受体及孕激受体存在，同时其阳性率与组织学分级、性别有明显关系，而与病理形态、年龄、淋巴结转移无关。该研究为选择性应用内分泌治疗食管鳞状上皮癌提供了理论依据。     

上颌窦鳞癌细胞雌激素、孕激素受体的研究

应用免疫组化ＡＢＣ法对５３例上颌窦鳞癌组织及２１例非癌组织（包括９例正常上颌窦组织、１２例上颌窦乳头状瘤组织）雌激素受体（ＥＲ）和孕激素受体（ＰＲ）的表达进行了检测。结果表明：上颌窦鳞癌的ＥＲ阳性率为４１．５１％，ＰＲ阳性率为３７．７４％；而非癌组织的ＥＲ、ＰＲ阳性率为９．５２％，差异有显著性（Ｐ＜０．０５）。表明部分上颌窦鳞癌组织中存在ＥＲ、ＰＲ、ＥＲ、ＰＲ表达密切相关（Ｐ＜０．００１）。上颌窦鳞癌细胞中ＥＲ、ＰＲ阳性率与组织学分级成反比，且在染色程度上有明显的差别。ＥＲ和ＰＲ的表达与年龄、性别无关（Ｐ＞０．０５）。本文有可能为上颌窦鳞癌患者的内分泌治疗提供参考。     

90例大肠癌雌,孕激素受体免疫组化检测研究

应用ＡＢＣ免疫组化法对９０例大肠癌石蜡切片进行雌激素受体（ＥＲ）、孕激素受体（ＰＲ）检测。结果发现ＥＲ、ＰＲ阳性率分别为６５．６％和５７．８％。高分化癌阳性率最高，高、中和低分化癌三者比较Ｐ〈０．００１，说明大肠癌分化程度越高，ＥＲ、ＰＲ阳性率也高，反之则低，呈正相关系。在大肠癌Ｄｕｋｅｓ分期中，以Ｃ期最低，Ａ、Ｂ、Ｃ三期比较，其Ｐ〈０．０２和〈０．０１，提示ＥＲ、ＰＲ阳性低的癌，其侵袭性强，生长     

脑膜瘤的雌孕激素受体

本文对３３例脑膜瘤的ＥＲ，ＰＲ作了分析。脑膜瘤性激素受体的阳性率：ＥＲｃ为０，ＥＲｎ为６．１％，ＰＲｃ为１２．１％，ＰＲｎ为６３．３％。多数肿瘤中测不到ＥＲ，且测到者含量变极低。ＰＲ含量明显高于ＥＲ，认为脑膜瘤以ＰＲ占优势。ＰＲ与ＥＲ间无相关关系，ＥＲｎ（ｇ ），ＰＲｎ（＋）者明显多于ＥＲｎ（＋），ＰＲｎ（＋）者，提示脑瘤的ＰＲ可能是一个不依赖于ＥＲ调节的独立系统。本资料为脑膜瘤的激素治疗可能性提     

Steroid receptor expression in thymomas and thymic carcinomas

BACKGROUND:

Although protein expressions of glucocorticoid receptor (GR), estrogen receptors (ERα and ERβ), progesterone receptor A (PgR‐A), and androgen receptor (AR) were shown to play roles in the growth and differentiation of normal thymus and thymic tumors, to the authors' knowledge their association with patient characteristics and prognosis has yet to be determined.

METHODS:

A series of 140 thymic epithelial tumors (57 type A + AB thymomas, 40 type B1 + B2 thymomas, 6 type B3 thymomas, and 37 thymic carcinomas) were examined for GR, ERα, ERβ, PgR‐A, and AR expression using immunohistochemistry. In addition, the correlation between expression of these hormone receptors and clinicopathologic factors and overall survival (OS) was assessed.

RESULTS:

GR and ERβ demonstrated a high rate of expression in thymomas and thymic carcinomas (82.9% and 76.4%, respectively), whereas rates of ERα, PgR‐A, and AR expression were low (13.6%, 0.71%, and 23.6%, respectively). A significant correlation (P < .05) was found between ERα expression and tumor size and between ERβ expression and tumor stage. Multivariate analyses revealed that histologic subtype (P = .0039), tumor stage (P = .0012), and GR expression (P = .0025) were significantly correlated with the 10‐year OS rate.

CONCLUSIONS:

GR and ERβ demonstrated high rates of expression in thymomas and thymic carcinomas. Furthermore, multivariate analysis revealed that GR expression was associated with better prognosis in patients with surgically resected thymomas and thymic carcinomas. Cancer 2011;. © 2011 American Cancer Society.     

甲状腺乳头状癌雌孕激素受体的检测临床及生物学意义

对１０５例甲状腺良、恶性疾病和２４例正常的甲状腺组织采用了酶联法进行雌孕激素受体的检测。乳头状癌，腺瘤、甲状腺肿以及正常的甲状腺组织的雌、孕激素受体阳性分别为５８．３％和４８．３％；３１．２％和２８．１％；３０．８％和３０．７％；２０．８％和１６．７％。乳头状腺癌的阳性率明显要高于甲状腺良性病变。在乳头状腺癌中，小于４５岁年龄组的雌激素受体的的阳性率明显要高于其它甲状腺病变。在乳头状腺癌中，小于４５岁的年龄组的雌激素受体的阳性率明显高于大于或等于４５岁的年龄组。雌、孕激素受体的阳性率和性别、病理分期，肿块大小，以及颈部淋巴结受累情况无关。二倍体乳头腺癌的雌激素受体阳性率要比异倍体肿瘤受体阳性率要高。     

大肠癌组织雌激素与孕酮受体检测的初步探讨

本文应用亲和酶标法检测了87例大肠癌组织及80例乳腺癌组织的雌激素受体(ER)和孕酮受体(PR),结果大肠癌的ER、PR阳性率分别为62.1％和46.0％;乳腺癌的ER、PR阳性率分别为65％和56.3％.大肠癌ER、PR阳性率与病人性别、肿瘤部位无关,而绝经后的大肠癌患者,年龄越大,肿瘤分化程度越高,受体阳性率亦越高,与乳腺癌相类似.提示大肠癌与乳癌一样为雌激素依赖性肿瘤,可试行内分泌治疗.     

Immunocytochemical localization of estrogen and progesterone receptor and prognosis in human primary breast cancer

An immunocytochemical assay (ICA) for the measurement of estrogen receptor (ER) and progesterone receptor (PgR) has been evaluated in 426 human primary breast carcinomas. For estrogen receptor determination ER ICA was used. PgR ICA was performed using the monoclonal antibody KD 68. Assay results for progesterone receptor immunocytochemistry were in agreement (P less than 0.0001) with those of biochemical determination in 74%. Progesterone receptor positivity determined with a semiquantified approach based on intensity and heterogeneity of immunocytochemical staining correlated significantly with biochemically determined progesterone receptor levels (P = 0.0001). Survival data showed a significantly better overall survival for patients with either ER ICA- or PgR ICA-positive carcinomas (ER ICA, P less than 0.00001; PgR ICA, P = 0.004). Patients with both negative ER ICA and PgR ICA showed a poorer prognosis than patients with only one negative receptor. In ER ICA- and PgR ICA-positive carcinomas a trend could be found that patients whose carcinomas contained high numbers of receptor-positive tumor cells had a better survival. This study demonstrates that ER ICA and PgR ICA are strong prognostic indicators and that the proportion of steroid hormone receptor-positive tumor cells seems to be of clinical importance.     

Results of two or five years of adjuvant tamoxifen correlated to steroid receptor and S-phase levels

A Swedish cooperative trial demonstrated that 5 years of adjuvant tamoxifen was more beneficial than 2 years of tamoxifen in the treatment of postmenopausal women with estrogen receptor (ER) positive, early stage, invasive breast cancer. The main aim of the present study was to investigate the importance of progesterone receptor (PgR) and ER concentration levels for patients participating in the trial and still distant recurrence free two years after the primary operation. Subgroup analyses revealed that only patients with ER positive and PgR positive breast cancer had improved distant recurrence free survival (DRFS) by prolonged tamoxifen therapy (p=0.0016). Patients with ER negative and PgR negative as well as ER positive and PgR negative tumors showed no significant effect of prolonged tamoxifen (p=0.53 and p=0.80, respectively). The percentage of ER negative and PgR positive breast cancers was too small (2.2%) for any meaningful subgroup analysis. There was a significant positive trend that the concentration level of PgR (high positive vs. low positive vs. negative) decreased the recurrence rate for those with prolonged therapy. No corresponding pattern was found for the ER content. S-phase fraction did not correlate to the recurrence rate of PgR positive breast cancers. Patients recurring during tamoxifen therapy had receptor negative tumors to a greater extent than those recurring after tamoxifen treatment.In conclusion, prolonged tamoxifen therapy for 5 years instead of 2 years was found to be beneficial for patients with ER positive and PgR positive breast cancer, whereas three extra years of tamoxifen had little or no effect for patients with ER positive but PgR negative tumors as well as for steroid receptor negative patients.     

Measurement of steroid hormone receptors in breast cancer patients on tamoxifen

Summary Estrogen (ER) and progesterone receptor (PgR) positive breast tumors often respond to tamoxifen, but ultimately progress as they become tamoxifen resistant. An accurate assessment of receptor status in specimens from tamoxifen-resistant patients could help to understand potential mechanisms of resistance and to predict response to second line hormonal therapies. However, since tamoxifen itself can affect ER and PgR determinations, assay results can be misleading. We measured ER and PgR by both ligand binding (LBA) and immunohistochemical (IHC) assays in 34 tumors from patients on tamoxifen, 30 of whom were displaying resistance to the drug. These tumors were classified into several receptor phenotypes. Eleven patients, 8 of whom were clearly progressing, expressed both receptors while on tamoxifen. ER was significantly less often negative when measured by IHC, suggesting that ER status by LBA was falsely negative in this group due to receptor occupancy by tamoxifen. Six patients had no detectable ER by LBA or IHC but still expressed PgR. The presence of PgR suggests that ER could still be functional, though undetectable, in these tumors, or that PgR is constitutively expressed by them. Finally, 12 patients were ER and PgR-negative by both assays, suggesting hormonal independence as the mechanism for resistance in this group. In a subset of patients with receptor assays both prior to tamoxifen and at the time of progression while taking the drug, we found that most ER-positive tumors converted to an apparent ER-negative status when assayed by LBA, while PgR status frequently remained unchanged. The continued expression of ER and/or PgR in many patients with tumor progression on tamoxifen indicates that mechanisms for resistance other than receptor loss are common in breast cancer.Deceased     

亲和组化法对消化道肿瘤雌,孕激素受体的细胞学研究

本文采用Ｅ２－ＨＲＰ、Ｐｇ－ＨＲＰ亲和组化法检测１００例消化道肿瘤的ＥＲ，ＰｇＲｏ结果表明：ＥＲ阳性者３７例（３７％），ＰｇＲ阳性者２２例（２２％），肿瘤的分化程度与ＥＲ，ＰｇＲ水平呈正相关。管状腺癌阳性率最高，胃肿瘤ＥＲ阳性率明显低于结，直肠癌，性别，年龄，临床分期与ＥＲ，ＰｇＲ主要存在于细胞核内与常染色质及核仁关系密切。     

Immunohistochemical image analysis of estrogen and progesterone receptors in breast cancer

Background  Recently objective quantification of immunohistochemical estrogen receptor (ER) and progesterone receptor (PgR) staining in breast cancer by image cytometry has been predominantly performed by measuring the area of positively stained cells. However, in sample preparations of immunostained hormone receptors, both the stained area and the intensity of staining vary. In this study, we performed quantification of the stained area by measuring, tailing intensity using image cytometry. Methods  Quantitative analysis of ER and PgR immunohistochemistry was performed using image cytometry. The obtained values were presented as % of positive staining (%PS). Comparison of %PS with values obtained by EIA and with clinicopathological features was performed. Results  The %PS values and the natural logarithm of the EIA levels of the hormone receptors showed a significant positive correlation for both ER and PgR. The concordance of the results obtained by the two methods was 96.3% for ER and 73.7% for PgR. The ER-%PS values of postmenopausal patients were significantly higher than those of premenopausal patients, whereas the PgR-%PS values of the former group were significantly lower than those of the latter group. Conclusions  The quantification of ER and PgR in immunostained preparations using %PS as a parameter was reproducible and showed a high correlation with values obtained by EIA. It was shown that only menopausal status affects hormone receptor levels when analyzing the relationship between %PS measurements and clinicopathological features.     

胃癌109例雌激素受体与孕激素受体的检测研究

自１９８６～１９９３年采用李氏荧光雌激素组织化学法对胃癌１０９创作了雌激素受体（ＥＲ）、孕激素受体（ＰｇＲ）测定，同时对８例非肿瘤病人的胃正常粘膜作了ＥＲ、ＰｇＲ测定。１０９例胃癌的ＥＲ、ＰｇＲ阳性率分别为２３％、２７．５％，８例非肿瘤病人的胃正常粘膜ＥＲ、ＰｇＲ均阴性。１０９例胃癌中高分化腺癌ＥＲ、ＰｇＲ阳性率分别为４４．１％（１５／３４）、４７．１％（１６／３４），均明显高于低分化腺癌的１４％（６／４３）及２０．９％（９／４３），ＥＲ为Ｐ＜０．０２、ＰｇＲ为Ｐ＜０．０５，发病年龄及性别与ＥＲ、ＰｇＲ均无关。认为ＥＲ、ＰｇＲ阳性的胃癌与雌激素靶器官的恶性肿瘤一样，可能为雌激素依赖性肿瘤，对内分泌治疗有着良好的前景。